Pulmonology
Asthma and COPD, pulmonary fibrosis, lung cancer and screening, sleep apnea, tuberculosis and infections, ventilation and respiratory care.
Published issues
- What's next in pulmonology — November 19, 2026
This issue covers four milestones with verifiable dates between January and May 2027: two applications under FDA review with a target or expected decision date communicated by the companies (inhaled amikacin liposome in…
🎧 ListenAudio newscast · 4:27 min - Monthly pulmonology bulletin — November 9, 2026
Period covered: October 10 to November 9, 2026. This issue includes only the items whose main figures could be checked against a primary document (an official release from the sponsor or from the regulator). The…
🎧 ListenAudio newscast · 3:07 min - What's next in pulmonology — October 19, 2026
This edition covers three pending regulatory decisions in the United States between January and late April 2027: amikacin liposome inhalation suspension in non-refractory MAC lung disease, tozorakimab in COPD, and…
🎧 ListenAudio newscast · 3:49 min - Monthly pulmonology bulletin — October 9, 2026
Period covered: September 9 to October 9, 2026. Note for this month: the month was dominated by the ERS Congress (Barcelona, September 5–9). Three of the most important items were presented on September 7–8, one or two…
🎧 ListenAudio newscast · 5:50 min - Monthly pulmonology bulletin — September 28, 2026
Period covered: August 28 to September 28, 2026. The month was dominated by the ERS Congress 2026 (Barcelona, September 5–9), which concentrated the most relevant phase III results in COPD, pulmonary hypertension and…
🎧 ListenAudio newscast · 6:11 min